Boehringer Ingelheim
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.15 | 9 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 3 | ×0.87 | 4 |
| approved | ×1.50 | 3 |
Strategy profile
Based on 15 disclosed transactions, Boehringer Ingelheim concentrates its licensing activity in Oncology, Option Deals, and Immunology. Boehringer Ingelheim pays a 1.15x premium over market median, with the strongest premiums in Oncology (1.15x). Their most common deal structure is Option, with an average disclosed value of $1.4B. Most recent activity: 2026.
Premium by therapeutic area
How Boehringer Ingelheim pays relative to peer medians in each TA
Pipeline coverage & gaps
Boehringer Ingelheim has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| OptionPrimary | 4 | $27M | $729M |
| CollaborationPrimary | 4 | $158M | $1.4B |
| License | 3 | $30M | $506M |
| Acquisition | 2 | $1.1B | $4.3B |
| Co Development | 2 | $93M | $994M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | CDR Life antibody/biologics program | CDR Life | — | unknown | — | $570M |
| 2026 | HTL-0048149 (GPR52 agonists) | Nxera Pharma | schizophrenia | preclinical | $28M | $830M |
| 2026 | HTL-0048149 (GPR52 agonists) | Nxera Pharma | schizophrenia | preclinical | $27M | $825M |
| 2026 | Immunitas inflammatory asset | Immunitas | inflammatory / autoimmune disorders | unknown | — | $448M |
| 2026 | undisclosed preclinical inflammatory disease asset | Immunitas Therapeutics | inflammatory disease | preclinical | — | $430M |
| 2025 | HTL-0048149 (GPR52 agonist) | Nxera Pharma | Schizophrenia | unknown | $28M | $831M |
| 2024 | checkpoint_inhibitor | Nerio Therapeutics | checkpoint_inhibitor | preclinical | $1.3B | $1.3B |
| 2024 | Ochre RNA program | Ochre Bio | MASH/NASH | preclinical | $35M | $1.3B |
| 2024 | SZN-413 (Wnt modulator for retina) | Surrozen | Diabetic retinopathy, DME | preclinical | $40M | $599M |
| 2024 | CTLA-4-201 | Astellas | Colorectal | phase_1 | $145M | $1.4B |
| 2023 | LBS-008 | Lin BioScience | Stargardt Disease, Geographic Atrophy | phase_2 | $30M | $500M |
| 2022 | Survodutide | Zealand Pharma | MASH, Obesity | phase_2 | $350M | $1.6B |
| 2020 | Cardiovascular RNAi therapeutics | Dicerna Pharmaceuticals | Cardiovascular Diseases | discovery | $200M | $2.0B |
| 2020 | CEA | Junshi Biosciences | T-cell Lymphoma | discovery | $46M | $772M |
| 2020 | PD-1 | Galapagos | Endometrial | phase_3 | $882M | $7.3B |
How this is computed
For each Boehringer Ingelheim deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 13 disclosed deal premiums vs. peer medians. Raw premium 1.147, clamped to [0.7, 1.5].